ResMed Inc. RMD
Set alert
As of Nov 2, 2:25 PM ET
- YTD
- -3.26%
- 1 year
- -5.62%
- Open
- 231.27
- Prev close
- 229.94
- Mkt cap
- 32.76B
- Vol
- 791.58K
- Avg vol
- 1.35M
- EPS
- 10.98
- P/E
- 21.21
- Div yield
- 1.04%
More statistics
- Low
- 227.73
- High
- 233.76
- Forward P/E
- 17.34
- Beta
- 0.75
- Short ratio
- 10.34
- Inst. own
- 73.30%
- Dividend
- 2.64
- Ex-div date
- Aug 19, 2026
- Earnings
- Jan 28, 2027
- 50-d avg
- 231.77
- 200-d avg
- 225.03
- 1y target
- 251.52
5D chart
Events in this range
- Oct 29, 2026Earnings: 2.91; estimate 2.69; surprise 8.18%
- Oct 30, 2026Rating: Keybanc · Overweight → Overweight
- Oct 30, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Oct 30, 2026Rating: RBC Capital · Outperform → Outperform
Signals (145)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2:15 PM | 10 minutes ago |
| RSI: Overbought | Nov 2, 1:25 PM | 1 hour ago |
| SMA: Bullish | Nov 2, 12:55 PM | 1 hour ago |
| SMA: Bullish | Nov 2, 12:55 PM | 1 hour ago |
| SMA: Bearish | Nov 2, 12:45 PM | 1 hour ago |
| SMA: Bearish | Nov 2, 12:45 PM | 1 hour ago |
| SMA: Bullish | Nov 2, 12:35 PM | 1 hour ago |
| SMA: Bullish | Nov 2, 12:35 PM | 1 hour ago |
| SMA: Bearish | Nov 2, 11:50 AM | 2 hours ago |
| SMA: Bearish | Nov 2, 11:50 AM | 2 hours ago |
| SMA: Bullish | Nov 2, 11:40 AM | 2 hours ago |
| MACD: Buy Signal | Nov 2, 11:05 AM | 3 hours ago |
| SMA: Bearish | Nov 2, 10:05 AM | 4 hours ago |
| SMA: Bullish | Nov 2, 10:00 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 9:35 AM | 4 hours ago |
| SMA: Bullish | Nov 2, 9:30 AM | 4 hours ago |
| SMA: Bullish | Nov 2, 9:30 AM | 4 hours ago |
| MACD: Sell Signal | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:35 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:50 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 30, 11:35 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:30 AM | 3 days ago |
| RSI: Oversold | Oct 30, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:00 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 2:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 12:15 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 11:00 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 1:25 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 28, 11:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 27, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:05 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:10 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 6 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:40 AM | 6 days ago |
News
10 hours ago fool.com
ResMed: 3 Key Takeaways for Long-Term Investors
ResMed reported that core constant currency revenue grew 7% in the first quarter. Patients on GLP-1 drugs are 11% more likely to start CPAP therapy.
-
2 days ago benzinga.com
Citigroup Maintains Neutral on ResMed, Raises Price Target to $270
Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Neutral and raises the price target from $240 to $270.
-
3 days ago benzinga.com
RBC Capital Maintains Outperform on ResMed, Raises Price Target to $288
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $262 to $288.
-
3 days ago benzinga.com
Wells Fargo Maintains Equal-Weight on ResMed, Raises Price Target to $250
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and raises the price target from $215 to $250.
3 days ago zacks.com
ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
-
3 days ago benzinga.com
Keybanc Maintains Overweight on ResMed, Raises Price Target to $277
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $267 to $277.
3 days ago zacks.com
RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth.
3 days ago marketbeat.com
What ResMed (RMD) Said on Its Q1 Earnings Call
ResMed NYSE: RMD reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks…
3 days ago seekingalpha.com
ResMed Inc. (RMD) Q1 2027 Earnings Call Transcript
ResMed Inc. (RMD) Q1 2027 Earnings Call Transcript
3 days ago zacks.com
ResMed (RMD) Beats Q1 Earnings and Revenue Estimates
ResMed (RMD) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.67 per share. This compares to earnings of $2.55 per share a year ago.
3 days ago benzinga.com
ResMed Q1 2027 Earnings Call Transcript
ResMed (NYSE:RMD) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below.
3 days ago benzinga.com
ResMed Q1 2027 Earnings Call Transcript
ResMed (NYSE:RMD) reported first-quarter financial results on Thursday. The transcript from the company’s first-quarter earnings call has been provided below.This transcript is brought to you by…
-
3 days ago benzinga.com
ResMed Sees FY2027 Adj EPS $12.00-$12.25 vs $12.09 Est; Sees Sales $5.750B-$5.850B vs $5.814B Est
ResMed (NYSE:RMD) is looking for FY2027 Adj EPS of $12.00-$12.25 vs $12.09 analyst estimate. sees sales of $5.750 billion-$5.850 billion vs $5.814 billion analyst estimate.
-
3 days ago benzinga.com
ResMed Q1 Adj. EPS $2.91 Beats $2.67 Estimate, Sales $1.415B Beat $1.392B Estimate
ResMed (NYSE:RMD) reported quarterly earnings of $2.91 per share which beat the analyst consensus estimate of $2.67 by 8.99 percent. This is a 14.12 percent increase over earnings of $2.55 per share…
3 days ago globenewswire.com
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
4 days ago zacks.com
Here's Why ResMed (RMD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
4 days ago benzinga.com
If You Invested $1000 In ResMed Stock 20 Years Ago, You Would Have This Much Today
ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 3.82% on an annualized basis producing an average annual return of 12.81%. Currently, ResMed has a market capitalization of…
5 days ago zacks.com
Unlocking Q1 Potential of ResMed (RMD): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the…
1 week ago zacks.com
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
1 week ago zacks.com
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
1 week ago zacks.com
ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock?
RMD heads into Q1 fiscal 2027 earnings with sleep device demand and new product launches supporting growth, while MatrixCare's divestiture weighs on revenues.
1 week ago zacks.com
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 weeks ago globenewswire.com
Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced the U.S.…
3 weeks ago benzinga.com
ResMed Q4 2026 Earnings Call Transcript
ResMed (NYSE:RMD) reported fourth-quarter financial results on Thursday. The transcript from the company's fourth-quarter earnings call has been provided below. Benzinga APIs provide real-time access…
3 weeks ago seekingalpha.com
Top 50 High-Quality Dividend Growth Stocks For October 2026
I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home…
3 weeks ago defenseworld.net
ResMed (NYSE:RMD) CEO Sells $1,129,613.03 in Stock
ResMed Inc. (NYSE: RMD - Get Free Report) CEO Michael Farrell sold 4,991 shares of the business's stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average…
3 weeks ago benzinga.com
Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7%
Stocks fell and small caps slumped Wednesday as the 30-year Treasury yield hit 5.7%, a 24-year high, with Fed minutes and bond auctions ahead.
1 month ago globenewswire.com
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday,…
1 month ago defenseworld.net
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
ResMed (NYSE: RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing…
1 month ago marketbeat.com
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
ResMed NYSE: RMD outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing…
-
1 month ago benzinga.com
RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262
RBC Capital analyst Craig Wong-Pan upgrades ResMed (NYSE:RMD) from Sector Perform to Outperform and raises the price target from $244 to $262.
-
2 months ago benzinga.com
Keybanc Maintains Overweight on ResMed, Raises Price Target to $267
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $255 to $267.
-
2 months ago benzinga.com
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230
Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.
-
2 months ago benzinga.com
RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $234 to $244.
-
2 months ago benzinga.com
Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225
Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:RMD) with a Neutral and lowers the price target from $233 to $225.
-
2 months ago benzinga.com
Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $260 to $255.
-
2 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $215
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers the price target from $225 to $215.
2 months ago benzinga.com
Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after weak Q2 results. Other stocks also lower premarket.
-
2 months ago benzinga.com
ResMed Q4 Adj. EPS $2.95 Beats $2.89 Estimate, Sales $1.464B Beat $1.459B Estimate
ResMed (NYSE:RMD) reported quarterly earnings of $2.95 per share which beat the analyst consensus estimate of $2.89 by 2.08 percent. This is a 15.69 percent increase over earnings of $2.55 per share…
-
3 months ago benzinga.com
Mizuho Maintains Outperform on ResMed, Lowers Price Target to $220
Mizuho analyst Anthony Petrone maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $235 to $220.
3 months ago benzinga.com
Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For Monday
Wall Street analysts change outlook on top names. Complete view of analyst rating changes including upgrades/downgrades. See analyst ratings page.
-
3 months ago benzinga.com
Citigroup Downgrades ResMed to Neutral, Lowers Price Target to $235
Citigroup analyst Laura Sutcliffe downgrades ResMed (NYSE:RMD) from Buy to Neutral and lowers the price target from $270 to $235.
-
3 months ago benzinga.com
Jefferies Maintains Hold on ResMed, Lowers Price Target to $225
Jefferies analyst Matthew Taylor maintains ResMed (NYSE:RMD) with a Hold and lowers the price target from $240 to $225.
3 months ago benzinga.com
ResMed Analyst Backs Portfolio Reset
ResMed is selling MatrixCare for $490 million to sharpen its sleep health focus as analysts weigh near-term EPS dilution against long-term growth.
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on ResMed, Lowers Price Target to $276
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $321 to $276.
-
3 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $225
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers the price target from $227 to $225.
-
3 months ago benzinga.com
ResMed Says Deal Valued At $490M All-Cash, Expected To Close In Q1 FY2027
On July 7, 2026, ResMed Inc. (the "Company" or "Resmed") issued a press release announcing that on June 30, 2026 it entered into a definitive agreement to sell its MatrixCare business to Frazier
-
3 months ago benzinga.com
Resmed Strikes Agreement To Sell Its MatrixCare Operations To Frazier Healthcare Partners; Financial Terms Undisclosed
Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its…
-
4 months ago benzinga.com
Keybanc Maintains Overweight on ResMed, Lowers Price Target to $266
Keybanc analyst Justin Patterson maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $290 to $266.
-
4 months ago benzinga.com
Here’s How Much You Would Have Made Owning ResMed Stock In The Last 20 Years
ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 1.89% on an annualized basis producing an average annual return of 11.28%. Currently, ResMed has a market capitalization of…